XML 38 R23.htm IDEA: XBRL DOCUMENT v3.24.3
SEGMENT INFORMATION
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
We are organized into three reporting segments. Operations that sell proprietary dispensing systems, drug delivery systems, sealing solutions and services to the prescription drug, consumer health care, injectables, active material science solutions and digital health markets form our Aptar Pharma segment. Operations that sell dispensing systems and sealing solutions to the beauty, personal care and home care markets form our Aptar Beauty segment. Operations that sell dispensing closures, sealing solutions and food service trays to the food, beverage, personal care, home care, beauty and healthcare markets form our Aptar Closures segment. Aptar Pharma and Aptar Beauty are named for the markets they serve with multiple product platforms, while Aptar Closures is named primarily for a single product platform that serves all available markets.
The accounting policies of the segments are the same as those described in Part II, Item 8, Note 1 - Summary of Significant Accounting Policies in our Annual Report on Form 10-K for the year ended December 31, 2023. We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items.
Financial information regarding our reporting segments is shown below:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2024202320242023
Total Sales:
Aptar Pharma$420,753 $389,423 $1,243,026 $1,136,544 
Aptar Beauty308,955 330,467 972,535 1,002,209 
Aptar Closures187,324 181,562 547,002 539,472 
Total Sales$917,032 $901,452 $2,762,563 $2,678,225 
Less: Intersegment Sales:
Aptar Pharma$159 $235 $606 $610 
Aptar Beauty6,096 6,487 20,869 22,253 
Aptar Closures1,486 1,733 6,286 6,392 
Total Intersegment Sales$7,741 $8,455 $27,761 $29,255 
Net Sales:
Aptar Pharma$420,594 $389,188 $1,242,420 $1,135,934 
Aptar Beauty302,859 323,980 951,666 979,956 
Aptar Closures185,838 179,829 540,716 533,080 
Net Sales$909,291 $892,997 $2,734,802 $2,648,970 
Adjusted EBITDA (1):
Aptar Pharma$151,594 $136,344 $425,260 $371,508 
Aptar Beauty40,221 41,070 125,993 121,375 
Aptar Closures31,980 27,607 86,259 81,387 
Corporate & Other, unallocated(15,411)(11,659)(57,528)(45,996)
Acquisition-related costs (2)— — (140)(255)
Restructuring Initiatives (3)(3,864)(6,161)(9,659)(19,628)
Curtailment gain related to restructuring initiatives (5)
1,851 — 1,851 — 
Net unrealized investment (loss) gain (4)1,043 (5,428)1,495 (2,349)
Depreciation and amortization(67,015)(62,686)(196,332)(184,212)
Interest Expense(12,290)(9,984)(32,526)(29,900)
Interest Income3,022 946 9,022 2,266 
Income before Income Taxes$131,131 $110,049 $353,695 $294,196 
________________________________________________
(1)We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items.
(2)Acquisition-related costs include transaction costs (and purchase accounting adjustments related to acquisitions and investments) (see Note 17 - Acquisitions and Note 18 – Investments in Equity Securities for further details).
(3)Restructuring Initiatives includes expense items for the three and nine months ended September 30, 2024 and 2023 as follows (see Note 19 – Restructuring Initiatives for further details):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2024202320242023
Restructuring Initiatives by Plan:
Optimization initiative$3,864 $6,586 $9,676 $20,069 
Prior year initiatives— (425)(17)(441)
Total Restructuring Initiatives$3,864 $6,161 $9,659 $19,628 
Restructuring Initiatives by Segment:
Aptar Pharma$564 $92 $653 $1,657 
Aptar Beauty1,962 2,880 5,871 12,650 
Aptar Closures877 3,098 2,530 4,060 
Corporate & Other461 91 605 1,261 
Total Restructuring Initiatives$3,864 $6,161 $9,659 $19,628 
(4)Net unrealized investment (loss) gain represents the change in fair value of our investment in PCT (see Note 18 – Investment in Equity Securities for further details).
(5)The curtailment gain is included in the line miscellaneous income (expense), net in the Condensed Consolidated Statements of Income (see Note 8 - Retirement and Deferred Compensation Plans).